Stock APLM APOLLOMICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Apollomics, Inc.

Equities

APLM

KYG0411D1079

Real-time Estimate Cboe BZX
Other stock markets
 01:59:44 2024-05-07 pm EDT 		5-day change 1st Jan Change
0.405 USD -3.55% Intraday chart for Apollomics, Inc. -5.21% -58.16%
Apr. 25 Avistone Biotechnology Co. Ltd. Receives Approval from the National Medical Products Administration of China for Vebrelinib (APL-101) for the Treatment of Gliomas with Met Fusion Gene CI
Apr. 05 Predicine, Inc. Announces Collaboration with Apollomics, Inc. to Develop Predicinecare as A Companion Diagnostic Assay in Lung Cancer CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
EF Hutton Cuts Price Target on Apollomics to $6.50 From $11, Maintains Buy Rating
MT
HC Wainwright Adjusts Apollomics' Price Target to $5 From $17, Maintains Buy Rating
MT
Apollomics Inc. Announces Efficacy of Vebrelinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate of 75%
CI
HC Wainwright Adjusts Price Target on Apollomics to $17 From $18, Maintains Buy Rating
MT
EF Hutton Assumes Apollomics at Buy With $25 Price Target
MT
HC Wainwright Initiates Apollomics at Buy With $18 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APLM Stock
  4. News Apollomics, Inc.
  5. Analyst Reco.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW